Good thing about CLDX is that they are modest in PR or Earnings call and despite so diverse platform they are not giving out any PR to hype the market. PBYI was the another example of modest and lucky companies for investors without being in limelight.
You may not like this but ....SRPT is dead cat finding all other opportunities to create a hype. EBOLA ...Common !!!!!!!!!CEO stop junking drug market.
CEO Chris Garbedien is a FRAUD and company SRPT itself is a huge fraud......Caveat Emptor !!!!!!!!!!!!!!!!!xxxxxxxxxxxx)))))))))))))))0000000000000000
Investors are falling all over themselves to buy into Puma Biotechnology (PBYI .... patient population, the drug did achieve survival times 30.8 months vs 20.6 months for a placebo in a sub-group but ... Celldex is a multi-product clinical stage biotechnology company, one with two ... related to the strong data from its breast cancer product CDX-011 is compared with Puma Biotechnology's neratinib but CDX011 is simply more effective.
This results are far more better than Puma Bio- PBYI but for CLDX its just only matter of time for everyone to know.
For all patients treated at the maximum dose level, tumor shrinkage was seen in 62% (16/26) and median PFS was 9.1 weeks. A subset of 10 patients had "triple negative disease," a more aggressive breast cancer subtype that carries a high risk of relapse and reduced survival as well as limited therapeutic options due to lack of over-expression of HER2/neu, estrogen and progesterone receptors. In these patients, 78% (7/9) had some tumor shrinkage, 12-week PFS rate was 70% (7/10), and median PFS was 17.9 weeks. Tumor samples from a subset of patients across all dose groups were analyzed for gpNMB expression. The tumor samples from most patients showed evidence of stromal and/or tumor cell expression of gpNMB.
If event 50 Interim results shows any positive indication in QTLY Earnings report then it would take this back into $30 range easily.
Interim results from 50% of events in the Act-IV trial are expected in the coming months. The Phase III trial in 700 newly diagnosed patients is testing the addition of rindopepimut to the current standard of care, temozolomide, with improvement in median overall survival as the primary outcome.
Last November interim data were released from the phase II React trial in recurrent glioblastoma. Results from the first 40 patients who were given rindopepimut and Avastin failed to show significant improvements in overall (p=0.16) or progression-free (p=0.47) survival (Celldex and ImmunoCellular fall and rise on hype and hope, November 26, 2013). Complete data are expected by the end of this year.
Note : neratinib is 33% - Glembatumumab vedotin (CDX-011) is already in accelerated approval and also results shows so far MORE THAN 25% in Antibody-Drug Conjugate Targeting GPNMB in Metastatic Breast Cancer and Metastatic Melanoma
Puma Biotech's Overnight Billionaire On One Of His Keys To Success
This story appears in the August 18, 2014 issue of Forbes.
Alan Auerbach hit the jackpot when stock of Puma Biotechnology, the drug company he founded, skyrocketed 295% on July 23 following good news from a Phase III clinical trial of an experimental breast cancer drug that Puma licensed from Pfizer. The astounding stock jump made him an overnight billionaire. Auerbach owns nearly 20% of the company, including 2.1 million warrants and 230,000 exercisable options. At the July 23 closing price of $233, Auerbach’s stake was worth over $1.3 billion
The drug, neratinib, improved disease-free survival by 33% compared to a placebo in women with early-stage HER2-positive breast cancer who were also taking Herceptin, a breast cancer drug from Roche Holding. Based on the results, Puma intends to apply for regulatory approval with the FDA in the first half of next year. “We are looking forward to getting this drug to patients,” says Auerbach, 44, Puma’s CEO.
Vaccines are becoming popular again – As PD-1 antibodies modulate the suppressive tumor microenvironment, they are viewed by many as enablers of cancer vaccines. PD-1 antibodies are expected to rime the immune system in general while vaccines will guide the immune system to the right antigens.
July 29, 2014
PFE Pfizer says will look at all deals 'regardless of size' Comment made on the Q2 earnings conference call.
$CLDX is designed phase 3 trial with $PFE last I heard, results from 110 very good despite no action after ASCO.